Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD. / Brikell, Isabell; Wimberley, Theresa; Albinana, Clara; Pedersen, Emil Michael; Vilhjalmsson, Bjarni Johann; Agerbo, Esben; Demontis, Ditte; Borglum, Anders D.; Schork, Andrew J.; LaBianca, Sonja; Werge, Thomas; Mors, Ole; Hougaard, David M.; Thapar, Anita; Mortensen, Preben Bo; Dalsgaard, Soren.
In: American Journal of Psychiatry, Vol. 178, No. 9, 2021, p. 854-864.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD
AU - Brikell, Isabell
AU - Wimberley, Theresa
AU - Albinana, Clara
AU - Pedersen, Emil Michael
AU - Vilhjalmsson, Bjarni Johann
AU - Agerbo, Esben
AU - Demontis, Ditte
AU - Borglum, Anders D.
AU - Schork, Andrew J.
AU - LaBianca, Sonja
AU - Werge, Thomas
AU - Mors, Ole
AU - Hougaard, David M.
AU - Thapar, Anita
AU - Mortensen, Preben Bo
AU - Dalsgaard, Soren
PY - 2021
Y1 - 2021
N2 - Objective: Stimulant medications are effective for treating attention deficit hyperactivity disorder (ADHD), yet discontinuation and switch to nonstimulant ADHD medications are common. This study aimed to identify genetic, clinical, and sociodemographic factors influencing stimulant treatment initiation, discontinuation, and switch to nonstimulants in individuals with ADHD.Methods: The authors obtained genetic and national register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample and defined stimulant treatment initiation, discontinuation, and switch from prescriptions. For each stimulant treatment outcome, they examined associations with polygenic risk scores (PRSs) for psychiatric disorders and clinical and sociodemographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated single-nucleotide polymorphism heritability (h(SNP)(2)).Results: Eighty-one percent of the sample initiated stimulant treatment. Within 2 years, 45% discontinued stimulants and 15% switched to nonstimulants. Bipolar disorder PRS (hazard ratio=1.05, 95% CI=1.02, 1.09) and schizophrenia PRS (hazard ratio=1.07, 95% CI=1.03, 1.11) were associated with discontinuation. Depression, bipolar disorder, and schizophrenia PRSs were marginally but not significantly associated with switch (hazard ratio range, 1.05-1.07). No associations were observed for ADHD and autism PRSs. Individuals diagnosed with ADHD at age 13 or older had higher rates of stimulant initiation, discontinuation, and switch (hazard ratio range, 1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (hazard ratio range, 0.84-0.88) and increased rates of discontinuation (hazard ratio range, 1.19-1.45) and switch (hazard ratio range, 1.40-2.08). h(SNP)(2) estimates were not significantly different from zero. No GWAS hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch.Conclusions: The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.
AB - Objective: Stimulant medications are effective for treating attention deficit hyperactivity disorder (ADHD), yet discontinuation and switch to nonstimulant ADHD medications are common. This study aimed to identify genetic, clinical, and sociodemographic factors influencing stimulant treatment initiation, discontinuation, and switch to nonstimulants in individuals with ADHD.Methods: The authors obtained genetic and national register data for 9,133 individuals with ADHD from the Danish iPSYCH2012 sample and defined stimulant treatment initiation, discontinuation, and switch from prescriptions. For each stimulant treatment outcome, they examined associations with polygenic risk scores (PRSs) for psychiatric disorders and clinical and sociodemographic factors using survival analyses, and conducted genome-wide association studies (GWASs) and estimated single-nucleotide polymorphism heritability (h(SNP)(2)).Results: Eighty-one percent of the sample initiated stimulant treatment. Within 2 years, 45% discontinued stimulants and 15% switched to nonstimulants. Bipolar disorder PRS (hazard ratio=1.05, 95% CI=1.02, 1.09) and schizophrenia PRS (hazard ratio=1.07, 95% CI=1.03, 1.11) were associated with discontinuation. Depression, bipolar disorder, and schizophrenia PRSs were marginally but not significantly associated with switch (hazard ratio range, 1.05-1.07). No associations were observed for ADHD and autism PRSs. Individuals diagnosed with ADHD at age 13 or older had higher rates of stimulant initiation, discontinuation, and switch (hazard ratio range, 1.27-2.01). Psychiatric comorbidities generally reduced rates of initiation (hazard ratio range, 0.84-0.88) and increased rates of discontinuation (hazard ratio range, 1.19-1.45) and switch (hazard ratio range, 1.40-2.08). h(SNP)(2) estimates were not significantly different from zero. No GWAS hits were identified for stimulant initiation or discontinuation. A locus on chromosome 16q23.3 reached genome-wide significance for switch.Conclusions: The study findings suggest that individuals with ADHD with higher polygenic liability for mood and/or psychotic disorders, delayed ADHD diagnosis, and psychiatric comorbidities have a higher risk for stimulant treatment discontinuation and switch to nonstimulants. Despite the study's limited sample size, one putative GWAS hit for switch was identified, illustrating the potential of utilizing genomics linked to prescription databases to advance ADHD pharmacogenomics.
KW - ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
KW - DRUG-TREATMENT
KW - MEDICATION
KW - CHILDREN
KW - RISK
KW - METHYLPHENIDATE
KW - DISCONTINUATION
KW - SCHIZOPHRENIA
KW - ADOLESCENTS
KW - DIAGNOSIS
U2 - 10.1176/appi.ajp.2020.20121686
DO - 10.1176/appi.ajp.2020.20121686
M3 - Journal article
C2 - 34154395
VL - 178
SP - 854
EP - 864
JO - The American Journal of Psychiatry
JF - The American Journal of Psychiatry
SN - 0002-953X
IS - 9
ER -
ID: 281655294